Metreleptin

(Myalept®)

Metreleptin

Drug updated on 9/4/2024

Dosage FormInjection (subcutaneous; sterile, white, solid, lyophilized cake of 11.3 mg metreleptin per vial to deliver 5 mg per mL when reconstituted in 2.2 mL of BWFI or WFI)
Drug ClassLeptin analogs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Myalept (metreleptin) is used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • Metreleptin reduces triglycerides and HbA1c in all lipodystrophy cases (n = 111) and in LMNA, PPARG, AGPAT2, and BSCL2 subgroups (n = 72, 13, 21, and 21, respectively). It lowers BMI in partial/generalized lipodystrophy and in LMNA or BSCL2 subgroups but not in PPARG or AGPAT2 subgroups.
  • Thiazolidinediones improve HbA1c and triglycerides in all lipodystrophy cases (n = 13) and show specific effectiveness in PPARG for HbA1c (n = 5) and LMNA for triglycerides (n = 7). Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) improves HbA1c in INSR-related insulin resistance (n = 17).
  • Eleven LEP deficiency patients benefitted from long-term metreleptin treatment, with one patient developing neutralizing antibodies leading to a loss of efficacy.
  • Safety outcomes beyond the development of neutralizing antibodies and hyperinsulinemia in LEP deficiency patients were not explicitly detailed in the reviewed studies.
  • Metreleptin shows effectiveness in LMNA, PPARG, AGPAT2, and BSCL2 genetic subgroups and benefits patients with LEP deficiency, though there is a risk of developing neutralizing antibodies leading to loss of efficacy; LEP deficiency patients are diagnosed younger with higher BMI SD scores and higher rates of hyperinsulinemia compared to LEPR deficiency patients, who are associated with missense variants.

Product Monograph / Prescribing Information

Document TitleYearSource
Myalept (metreleptin) prescribing information.2022Amryt Pharmaceuticals DAC, Dublin, Ireland

Systematic Reviews / Meta-Analyses